Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Pneumonia Testing Market by Types (Consumables, Analyzers), by Method (Immunodiagnostics, Molecular Diagnostics, Point of Care Testing), by Technology (Enzyme Linked Immunosorbant Assay, Immunofluoroscence, Western Blot, Polymerase Chain Reaction, Imunohistochemistry, Others), by End User (Hospitals, Diagnostic Laboratories, Homecare, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

A03434

Pages: 180

Charts: 66

Tables: 182

The global Pneumonia Testing Market size was valued at $1.6 billion in 2020, and is projected to reach $3.0 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030. Pneumonia is a complicated infection that affects the lower respiratory tract and is characterized by symptoms, such as short breathing, fever, chest pain, nausea, and vomiting. Air sacs of the lungs called as alveoli are filled with fluid or pus that cause inflammation during pneumonia. It is mainly caused by microorganisms, such as bacteria, virus, fungi, and parasites, which affects people with weakened immune systems and is common in children and the geriatric population. The treatment of pneumonia depends on the severity of symptoms and types of pathogens. Antibiotics are given to treat pneumonia caused by bacterial infections. Antifungals are prescribed to treat pneumonia caused by fungi. It is quite difficult to diagnose pneumonia as its clinical symptoms overlap with many other diseases, such as asthma, bronchitis, and the common cold.

[COVIDIMPACTSTATEMENT]

The key factor that drives the Pneumonia Testing Market Growth is a rise in the adoption of point of care(POC) testing and development in the field of nucleic acid detection across the world. In addition, increase in the geriatric population, the surge in advances in pneumonia diagnostics, and growth in prevalence of pneumonia among children across the globe fuel the growth of the market. Furthermore, increase in healthcare expenditure, presence of advanced healthcare infrastructure, availability of reimbursements, and the presence of key market players are Pneumonia Testing Market Opportunity, However, the traditional method, cultures are still mostly used to detect pneumonia causative organisms which can hamper the market growth to a certain extent during the forecast period as this traditional method is a time-consuming process with a higher error rate.

The Pneumonia Testing Industryis segmented on the basis of method, technology, type & end user . Depending on the method, it is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. By type, it is bifurcated into analyzers and consumables. Based on technology, it is categorized into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. As per end users, it is segregated into hospitals, diagnostic laboratories, home care, and others. Region-wise the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

[METHODGRAPH]

By Method Segment Review

Depending on the method, the point-of-care (POC) testing segment holds the largest market and is expected to witness the highest CAGR during the forecast period. prevalence of pneumonia across the world, due to various reasons, such as an increase in the geriatric population, sedentary lifestyles, unhealthy food habits, and environmental factors.

[TYPESGRAPH]

By Type Segment Review

By type, the analyzers segment holds the largest market share in 2020 and is expected to remain dominant in thePneumonia Testing Market Forecast, owing to their frequent usage for pneumonia tests are the key factors anticipating the growth of the market.

[TECHNOLOGYGRAPH]

By Technology Segment Review

As per technology, the enzyme-linked immunosorbent assay segment holds the largest market share in 2020 and is expected to remain dominant during the forecast period. An increase in demand for advanced diagnostic techniques and a rise in a number of contract research organizations (CROs) are the key factors anticipating the growth of the market in the future.

 

[ENDUSERGRAPH]

By End-user Segment Review

By end-user, the hospital segment is the major contributor to the market growth, owing to the increase in the number of patients suffering from pneumonia and the rise in the demand for diagnostic tests across the globe.

[REGIONGRAPH]

Region segment Review

Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America has the highest Pneumonia Testing Market Share in 2020, owing to a rise in prevalence of chronic diseases, growth in healthcare expenditure, the surge in presence of advanced healthcare infrastructure, increase in the availability of reimbursements, and rise in presence of major market players in the region are the major factors driving the growth of the pneumonia testing market in North America.

The key players operating in the Pneumonia Testing Industry include Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., BioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pneumonia testing market analysis from 2020 to 2030 to identify the prevailing pneumonia testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pneumonia testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pneumonia testing market trends, key players, market segments, application areas, and market growth strategies.

 

Key Market Segments

  • By Type
    • Consumables
    • Analyzers
  • By Method
    • Molecular Diagnostics
    • Point of Care Testing
    • Immunodiagnostics
  • By Technology
    • Enzyme Linked Immunosorbant Assay
    • Immunofluoroscence
    • Western Blot
    • Polymerase Chain Reaction
    • Imunohistochemistry
    • Others
  • By End User
    • Hospitals
    • Diagnostic Laboratories
    • Homecare
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest Of Asia Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA


Key Market Players

  • Beckman Coulter
  • Bio Rad laborateries
  • Quidel Corporation
  • AdvanDx
  • Abott Laboratories
  • Biomerieux SA
  • Beckton and Dickinson Company
  • F.hoffman La roche
  • Thermofischer Inc
  • Hologic Inc
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: PNEUMONIA TESTING MARKET, BY TYPES

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Consumables

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Analyzers

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

  • CHAPTER 5: PNEUMONIA TESTING MARKET, BY METHOD

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Immunodiagnostics

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Molecular Diagnostics

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Point of Care Testing

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

  • CHAPTER 6: PNEUMONIA TESTING MARKET, BY TECHNOLOGY

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Enzyme Linked Immunosorbant Assay

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Immunofluoroscence

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

    • 6.4 Western Blot

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market analysis by country

    • 6.5 Polymerase Chain Reaction

      • 6.5.1 Key market trends, growth factors and opportunities

      • 6.5.2 Market size and forecast, by region

      • 6.5.3 Market analysis by country

    • 6.6 Imunohistochemistry

      • 6.6.1 Key market trends, growth factors and opportunities

      • 6.6.2 Market size and forecast, by region

      • 6.6.3 Market analysis by country

    • 6.7 Others

      • 6.7.1 Key market trends, growth factors and opportunities

      • 6.7.2 Market size and forecast, by region

      • 6.7.3 Market analysis by country

  • CHAPTER 7: PNEUMONIA TESTING MARKET, BY END USER

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 Hospitals

      • 7.2.1 Key market trends, growth factors and opportunities

      • 7.2.2 Market size and forecast, by region

      • 7.2.3 Market analysis by country

    • 7.3 Diagnostic Laboratories

      • 7.3.1 Key market trends, growth factors and opportunities

      • 7.3.2 Market size and forecast, by region

      • 7.3.3 Market analysis by country

    • 7.4 Homecare

      • 7.4.1 Key market trends, growth factors and opportunities

      • 7.4.2 Market size and forecast, by region

      • 7.4.3 Market analysis by country

    • 7.5 Others

      • 7.5.1 Key market trends, growth factors and opportunities

      • 7.5.2 Market size and forecast, by region

      • 7.5.3 Market analysis by country

  • CHAPTER 8: PNEUMONIA TESTING MARKET, BY REGION

    • 8.1 Overview

      • 8.1.1 Market size and forecast

    • 8.2 North America

      • 8.2.1 Key trends and opportunities

      • 8.2.2 North America Market size and forecast, by Types

      • 8.2.3 North America Market size and forecast, by Method

      • 8.2.4 North America Market size and forecast, by Technology

      • 8.2.5 North America Market size and forecast, by End User

      • 8.2.6 North America Market size and forecast, by country

        • 8.2.6.1 U.S.
          • 8.2.6.1.1 Market size and forecast, by Types
          • 8.2.6.1.2 Market size and forecast, by Method
          • 8.2.6.1.3 Market size and forecast, by Technology
          • 8.2.6.1.4 Market size and forecast, by End User
        • 8.2.6.2 Canada
          • 8.2.6.2.1 Market size and forecast, by Types
          • 8.2.6.2.2 Market size and forecast, by Method
          • 8.2.6.2.3 Market size and forecast, by Technology
          • 8.2.6.2.4 Market size and forecast, by End User
        • 8.2.6.3 Mexico
          • 8.2.6.3.1 Market size and forecast, by Types
          • 8.2.6.3.2 Market size and forecast, by Method
          • 8.2.6.3.3 Market size and forecast, by Technology
          • 8.2.6.3.4 Market size and forecast, by End User
    • 8.3 Europe

      • 8.3.1 Key trends and opportunities

      • 8.3.2 Europe Market size and forecast, by Types

      • 8.3.3 Europe Market size and forecast, by Method

      • 8.3.4 Europe Market size and forecast, by Technology

      • 8.3.5 Europe Market size and forecast, by End User

      • 8.3.6 Europe Market size and forecast, by country

        • 8.3.6.1 Germany
          • 8.3.6.1.1 Market size and forecast, by Types
          • 8.3.6.1.2 Market size and forecast, by Method
          • 8.3.6.1.3 Market size and forecast, by Technology
          • 8.3.6.1.4 Market size and forecast, by End User
        • 8.3.6.2 France
          • 8.3.6.2.1 Market size and forecast, by Types
          • 8.3.6.2.2 Market size and forecast, by Method
          • 8.3.6.2.3 Market size and forecast, by Technology
          • 8.3.6.2.4 Market size and forecast, by End User
        • 8.3.6.3 U.K.
          • 8.3.6.3.1 Market size and forecast, by Types
          • 8.3.6.3.2 Market size and forecast, by Method
          • 8.3.6.3.3 Market size and forecast, by Technology
          • 8.3.6.3.4 Market size and forecast, by End User
        • 8.3.6.4 Italy
          • 8.3.6.4.1 Market size and forecast, by Types
          • 8.3.6.4.2 Market size and forecast, by Method
          • 8.3.6.4.3 Market size and forecast, by Technology
          • 8.3.6.4.4 Market size and forecast, by End User
        • 8.3.6.5 Spain
          • 8.3.6.5.1 Market size and forecast, by Types
          • 8.3.6.5.2 Market size and forecast, by Method
          • 8.3.6.5.3 Market size and forecast, by Technology
          • 8.3.6.5.4 Market size and forecast, by End User
        • 8.3.6.6 Rest of Europe
          • 8.3.6.6.1 Market size and forecast, by Types
          • 8.3.6.6.2 Market size and forecast, by Method
          • 8.3.6.6.3 Market size and forecast, by Technology
          • 8.3.6.6.4 Market size and forecast, by End User
    • 8.4 Asia-Pacific

      • 8.4.1 Key trends and opportunities

      • 8.4.2 Asia-Pacific Market size and forecast, by Types

      • 8.4.3 Asia-Pacific Market size and forecast, by Method

      • 8.4.4 Asia-Pacific Market size and forecast, by Technology

      • 8.4.5 Asia-Pacific Market size and forecast, by End User

      • 8.4.6 Asia-Pacific Market size and forecast, by country

        • 8.4.6.1 Japan
          • 8.4.6.1.1 Market size and forecast, by Types
          • 8.4.6.1.2 Market size and forecast, by Method
          • 8.4.6.1.3 Market size and forecast, by Technology
          • 8.4.6.1.4 Market size and forecast, by End User
        • 8.4.6.2 China
          • 8.4.6.2.1 Market size and forecast, by Types
          • 8.4.6.2.2 Market size and forecast, by Method
          • 8.4.6.2.3 Market size and forecast, by Technology
          • 8.4.6.2.4 Market size and forecast, by End User
        • 8.4.6.3 Australia
          • 8.4.6.3.1 Market size and forecast, by Types
          • 8.4.6.3.2 Market size and forecast, by Method
          • 8.4.6.3.3 Market size and forecast, by Technology
          • 8.4.6.3.4 Market size and forecast, by End User
        • 8.4.6.4 India
          • 8.4.6.4.1 Market size and forecast, by Types
          • 8.4.6.4.2 Market size and forecast, by Method
          • 8.4.6.4.3 Market size and forecast, by Technology
          • 8.4.6.4.4 Market size and forecast, by End User
        • 8.4.6.5 South Korea
          • 8.4.6.5.1 Market size and forecast, by Types
          • 8.4.6.5.2 Market size and forecast, by Method
          • 8.4.6.5.3 Market size and forecast, by Technology
          • 8.4.6.5.4 Market size and forecast, by End User
        • 8.4.6.6 Rest Of Asia Pacific
          • 8.4.6.6.1 Market size and forecast, by Types
          • 8.4.6.6.2 Market size and forecast, by Method
          • 8.4.6.6.3 Market size and forecast, by Technology
          • 8.4.6.6.4 Market size and forecast, by End User
    • 8.5 LAMEA

      • 8.5.1 Key trends and opportunities

      • 8.5.2 LAMEA Market size and forecast, by Types

      • 8.5.3 LAMEA Market size and forecast, by Method

      • 8.5.4 LAMEA Market size and forecast, by Technology

      • 8.5.5 LAMEA Market size and forecast, by End User

      • 8.5.6 LAMEA Market size and forecast, by country

        • 8.5.6.1 Brazil
          • 8.5.6.1.1 Market size and forecast, by Types
          • 8.5.6.1.2 Market size and forecast, by Method
          • 8.5.6.1.3 Market size and forecast, by Technology
          • 8.5.6.1.4 Market size and forecast, by End User
        • 8.5.6.2 Saudi Arabia
          • 8.5.6.2.1 Market size and forecast, by Types
          • 8.5.6.2.2 Market size and forecast, by Method
          • 8.5.6.2.3 Market size and forecast, by Technology
          • 8.5.6.2.4 Market size and forecast, by End User
        • 8.5.6.3 South Africa
          • 8.5.6.3.1 Market size and forecast, by Types
          • 8.5.6.3.2 Market size and forecast, by Method
          • 8.5.6.3.3 Market size and forecast, by Technology
          • 8.5.6.3.4 Market size and forecast, by End User
        • 8.5.6.4 Rest of LAMEA
          • 8.5.6.4.1 Market size and forecast, by Types
          • 8.5.6.4.2 Market size and forecast, by Method
          • 8.5.6.4.3 Market size and forecast, by Technology
          • 8.5.6.4.4 Market size and forecast, by End User
  • CHAPTER 9: COMPANY LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top winning strategies

    • 9.3. Product Mapping of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Key developments

  • CHAPTER 10: COMPANY PROFILES

    • 10.1 Abott Laboratories

      • 10.1.1 Company overview

      • 10.1.2 Company snapshot

      • 10.1.3 Operating business segments

      • 10.1.4 Product portfolio

      • 10.1.5 Business performance

      • 10.1.6 Key strategic moves and developments

    • 10.2 F.hoffman La roche

      • 10.2.1 Company overview

      • 10.2.2 Company snapshot

      • 10.2.3 Operating business segments

      • 10.2.4 Product portfolio

      • 10.2.5 Business performance

      • 10.2.6 Key strategic moves and developments

    • 10.3 Thermofischer Inc

      • 10.3.1 Company overview

      • 10.3.2 Company snapshot

      • 10.3.3 Operating business segments

      • 10.3.4 Product portfolio

      • 10.3.5 Business performance

      • 10.3.6 Key strategic moves and developments

    • 10.4 Hologic Inc

      • 10.4.1 Company overview

      • 10.4.2 Company snapshot

      • 10.4.3 Operating business segments

      • 10.4.4 Product portfolio

      • 10.4.5 Business performance

      • 10.4.6 Key strategic moves and developments

    • 10.5 Biomerieux SA

      • 10.5.1 Company overview

      • 10.5.2 Company snapshot

      • 10.5.3 Operating business segments

      • 10.5.4 Product portfolio

      • 10.5.5 Business performance

      • 10.5.6 Key strategic moves and developments

    • 10.6 Quidel Corporation

      • 10.6.1 Company overview

      • 10.6.2 Company snapshot

      • 10.6.3 Operating business segments

      • 10.6.4 Product portfolio

      • 10.6.5 Business performance

      • 10.6.6 Key strategic moves and developments

    • 10.7 Bio Rad laborateries

      • 10.7.1 Company overview

      • 10.7.2 Company snapshot

      • 10.7.3 Operating business segments

      • 10.7.4 Product portfolio

      • 10.7.5 Business performance

      • 10.7.6 Key strategic moves and developments

    • 10.8 Beckton and Dickinson Company

      • 10.8.1 Company overview

      • 10.8.2 Company snapshot

      • 10.8.3 Operating business segments

      • 10.8.4 Product portfolio

      • 10.8.5 Business performance

      • 10.8.6 Key strategic moves and developments

    • 10.9 AdvanDx

      • 10.9.1 Company overview

      • 10.9.2 Company snapshot

      • 10.9.3 Operating business segments

      • 10.9.4 Product portfolio

      • 10.9.5 Business performance

      • 10.9.6 Key strategic moves and developments

    • 10.10 Beckman Coulter

      • 10.10.1 Company overview

      • 10.10.2 Company snapshot

      • 10.10.3 Operating business segments

      • 10.10.4 Product portfolio

      • 10.10.5 Business performance

      • 10.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
    TABLE 2. PNEUMONIA TESTING MARKET REVENUE, FOR CONSUMABLES, BY REGION , 2020-2030,($MILLION)
    TABLE 3. PNEUMONIA TESTING MARKET CONSUMABLES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 4. PNEUMONIA TESTING MARKET REVENUE, FOR ANALYZERS, BY REGION , 2020-2030,($MILLION)
    TABLE 5. PNEUMONIA TESTING MARKET ANALYZERS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 6. GLOBAL PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
    TABLE 7. PNEUMONIA TESTING MARKET REVENUE, FOR IMMUNODIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
    TABLE 8. PNEUMONIA TESTING MARKET IMMUNODIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 9. PNEUMONIA TESTING MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
    TABLE 10. PNEUMONIA TESTING MARKET MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 11. PNEUMONIA TESTING MARKET REVENUE, FOR POINT OF CARE TESTING, BY REGION , 2020-2030,($MILLION)
    TABLE 12. PNEUMONIA TESTING MARKET POINT OF CARE TESTING BY COUNTRY, 2020-2030,($MILLION)
    TABLE 13. GLOBAL PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
    TABLE 14. PNEUMONIA TESTING MARKET REVENUE, FOR ENZYME LINKED IMMUNOSORBANT ASSAY, BY REGION , 2020-2030,($MILLION)
    TABLE 15. PNEUMONIA TESTING MARKET ENZYME LINKED IMMUNOSORBANT ASSAY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 16. PNEUMONIA TESTING MARKET REVENUE, FOR IMMUNOFLUOROSCENCE, BY REGION , 2020-2030,($MILLION)
    TABLE 17. PNEUMONIA TESTING MARKET IMMUNOFLUOROSCENCE BY COUNTRY, 2020-2030,($MILLION)
    TABLE 18. PNEUMONIA TESTING MARKET REVENUE, FOR WESTERN BLOT, BY REGION , 2020-2030,($MILLION)
    TABLE 19. PNEUMONIA TESTING MARKET WESTERN BLOT BY COUNTRY, 2020-2030,($MILLION)
    TABLE 20. PNEUMONIA TESTING MARKET REVENUE, FOR POLYMERASE CHAIN REACTION, BY REGION , 2020-2030,($MILLION)
    TABLE 21. PNEUMONIA TESTING MARKET POLYMERASE CHAIN REACTION BY COUNTRY, 2020-2030,($MILLION)
    TABLE 22. PNEUMONIA TESTING MARKET REVENUE, FOR IMUNOHISTOCHEMISTRY, BY REGION , 2020-2030,($MILLION)
    TABLE 23. PNEUMONIA TESTING MARKET IMUNOHISTOCHEMISTRY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 24. PNEUMONIA TESTING MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
    TABLE 25. PNEUMONIA TESTING MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 26. GLOBAL PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 27. PNEUMONIA TESTING MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION)
    TABLE 28. PNEUMONIA TESTING MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 29. PNEUMONIA TESTING MARKET REVENUE, FOR DIAGNOSTIC LABORATORIES, BY REGION , 2020-2030,($MILLION)
    TABLE 30. PNEUMONIA TESTING MARKET DIAGNOSTIC LABORATORIES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 31. PNEUMONIA TESTING MARKET REVENUE, FOR HOMECARE, BY REGION , 2020-2030,($MILLION)
    TABLE 32. PNEUMONIA TESTING MARKET HOMECARE BY COUNTRY, 2020-2030,($MILLION)
    TABLE 33. PNEUMONIA TESTING MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
    TABLE 34. PNEUMONIA TESTING MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 35. PNEUMONIA TESTING MARKET, BY REGION, 2020-2030,($MILLION)
    TABLE 36. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
    TABLE 37. NORTH AMERICA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
    TABLE 38. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
    TABLE 39. NORTH AMERICA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 40. NORTH AMERICA PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 41. U.S. PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 42. U.S. PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 43. U.S. PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 44. U.S. PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 45. CANADA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 46. CANADA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 47. CANADA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 48. CANADA PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 49. MEXICO PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 50. MEXICO PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 51. MEXICO PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 52. MEXICO PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 53. EUROPE PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
    TABLE 54. EUROPE PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
    TABLE 55. EUROPE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
    TABLE 56. EUROPE PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 57. EUROPE PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 58. GERMANY PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 59. GERMANY PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 60. GERMANY PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 61. GERMANY PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 62. FRANCE PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 63. FRANCE PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 64. FRANCE PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 65. FRANCE PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 66. U.K. PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 67. U.K. PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 68. U.K. PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 69. U.K. PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 70. ITALY PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 71. ITALY PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 72. ITALY PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 73. ITALY PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 74. SPAIN PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 75. SPAIN PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 76. SPAIN PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 77. SPAIN PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 78. REST OF EUROPE PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 79. REST OF EUROPE PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 80. REST OF EUROPE PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 81. REST OF EUROPE PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 82. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
    TABLE 83. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
    TABLE 84. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
    TABLE 85. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 86. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 87. JAPAN PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 88. JAPAN PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 89. JAPAN PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 90. JAPAN PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 91. CHINA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 92. CHINA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 93. CHINA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 94. CHINA PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 95. AUSTRALIA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 96. AUSTRALIA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 97. AUSTRALIA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 98. AUSTRALIA PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 99. INDIA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 100. INDIA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 101. INDIA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 102. INDIA PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 103. SOUTH KOREA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 104. SOUTH KOREA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 105. SOUTH KOREA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 106. SOUTH KOREA PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 107. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 108. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 109. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 110. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 111. LAMEA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
    TABLE 112. LAMEA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
    TABLE 113. LAMEA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
    TABLE 114. LAMEA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 115. LAMEA PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 116. BRAZIL PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 117. BRAZIL PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 118. BRAZIL PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 119. BRAZIL PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 120. SAUDI ARABIA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 121. SAUDI ARABIA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 122. SAUDI ARABIA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 123. SAUDI ARABIA PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 124. SOUTH AFRICA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 125. SOUTH AFRICA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 126. SOUTH AFRICA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 127. SOUTH AFRICA PNEUMONIA TESTING MARKET BY END-USER 2020-2030,($MILLION)
    TABLE 128. REST OF LAMEA PNEUMONIA TESTING MARKET BY TYPES 2020-2030,($MILLION)
    TABLE 129. REST OF LAMEA PNEUMONIA TESTING MARKET BY METHOD 2020-2030,($MILLION)
    TABLE 130. REST OF LAMEA PNEUMONIA TESTING MARKET BY TECHNOLOGY 2020-2030,($MILLION)
    TABLE 131. REST OF LAMEA PNEUMONIA TESTING MARKET BY END USER 2020-2030,($MILLION)
    TABLE 132.ABBOTT LABORATORIES: COMPANY SNAPSHOT
    TABLE 133.ABBOTT LABORATORIES: OPERATING SEGMENTS
    TABLE 134.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
    TABLE 135.ABBOTT LABORATORIES: NET SALES,
    TABLE 136.ABBOTT LABORATORIES: KEY STRATEGIES
    TABLE 137.F.HOFFMAN LA ROCHE: COMPANY SNAPSHOT
    TABLE 138.F.HOFFMAN LA ROCHE: OPERATING SEGMENTS
    TABLE 139.F.HOFFMAN LA ROCHE: PRODUCT PORTFOLIO
    TABLE 140.F.HOFFMAN LA ROCHE: NET SALES,
    TABLE 141.F.HOFFMAN LA ROCHE: KEY STRATERGIES
    TABLE 142.THERMOFISCHER INC: COMPANY SNAPSHOT
    TABLE 143.THERMOFISCHER INC: OPERATING SEGMENTS
    TABLE 144.THERMOFISCHER INC: PRODUCT PORTFOLIO
    TABLE 145.THERMOFISCHER INC: NET SALES,
    TABLE 146.THERMOFISCHER INC: KEY STRATERGIES
    TABLE 147.HOLOGIC INC: COMPANY SNAPSHOT
    TABLE 148.HOLOGIC INC: OPERATING SEGMENTS
    TABLE 149.HOLOGIC INC: PRODUCT PORTFOLIO
    TABLE 150.HOLOGIC INC: NET SALES,
    TABLE 151.HOLOGIC INC: KEY STRATEGIES
    TABLE 152.BIOMERIEUX SA: COMPANY SNAPSHOT
    TABLE 153.BIOMERIEUX SA: OPERATING SEGMENTS
    TABLE 154.BIOMERIEUX SA: PRODUCT PORTFOLIO
    TABLE 155.BIOMERIEUX SA: NET SALES,
    TABLE 156.BIOMERIEUX SA: KEY STRATERGIES
    TABLE 157.QUIDEL CORPORATION: COMPANY SNAPSHOT
    TABLE 158.QUIDEL CORPORATION: OPERATING SEGMENTS
    TABLE 159.QUIDEL CORPORATION: PRODUCT PORTFOLIO
    TABLE 160.QUIDEL CORPORATION: NET SALES,
    TABLE 161.QUIDEL CORPORATION: KEY STRATEGIES
    TABLE 162.BIO RAD LABORATORIES: COMPANY SNAPSHOT
    TABLE 163.BIO RAD LABORATORIES: OPERATING SEGMENTS
    TABLE 164.BIO RAD LABORATORIES: PRODUCT PORTFOLIO
    TABLE 165.BIO RAD LABORATORIES: NET SALES,
    TABLE 166.BIO RAD LABORATORIES: KEY STRATEGIES
    TABLE 167.BECKTON AND DICKINSON COMPANY: COMPANY SNAPSHOT
    TABLE 168.BECKTON AND DICKINSON COMPANY: OPERATING SEGMENTS
    TABLE 169.BECKTON AND DICKINSON COMPANY: PRODUCT PORTFOLIO
    TABLE 170.BECKTON AND DICKINSON COMPANY: NET SALES,
    TABLE 171.BECKTON AND DICKINSON COMPANY: KEY STRATEGIES
    TABLE 172.ADVANDX: COMPANY SNAPSHOT
    TABLE 173.ADVANDX: OPERATING SEGMENTS
    TABLE 174.ADVANDX: PRODUCT PORTFOLIO
    TABLE 175.ADVANDX: NET SALES,
    TABLE 176.ADVANDX: KEY STRATEGIES
    TABLE 177.BECKMAN COULTER: COMPANY SNAPSHOT
    TABLE 178.BECKMAN COULTER: OPERATING SEGMENTS
    TABLE 179.BECKMAN COULTER: PRODUCT PORTFOLIO
    TABLE 180.BECKMAN COULTER: NET SALES,
    TABLE 181.BECKMAN COULTER: KEY STRATEGIES
  • LIST OF FIGURES

  • FIGURE 1.PNEUMONIA TESTING MARKET SEGMENTATION
    FIGURE 2.PNEUMONIA TESTING MARKET,2020-2030
    FIGURE 3.PNEUMONIA TESTING MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.PNEUMONIA TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.PNEUMONIA TESTING MARKET,BY TYPES,2020(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CONSUMABLES PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANALYZERS PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 15.PNEUMONIA TESTING MARKET,BY METHOD,2020(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF IMMUNODIAGNOSTICS PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTICS PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF POINT OF CARE TESTING PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 19.PNEUMONIA TESTING MARKET,BY TECHNOLOGY,2020(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ENZYME LINKED IMMUNOSORBANT ASSAY PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF IMMUNOFLUOROSCENCE PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF WESTERN BLOT PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF POLYMERASE CHAIN REACTION PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF IMUNOHISTOCHEMISTRY PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 26.PNEUMONIA TESTING MARKET,BY END USER,2020(%)
    FIGURE 27.COMPARATIVE SHARE ANALYSIS OF HOSPITALS PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 28.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC LABORATORIES PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 29.COMPARATIVE SHARE ANALYSIS OF HOMECARE PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHERS PNEUMONIA TESTING MARKET,2020-2030(%)
    FIGURE 31.PNEUMONIA TESTING MARKET BY REGION,2020
    FIGURE 32.U.S. PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 33.CANADA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 34.MEXICO PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 35.GERMANY PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 36.FRANCE PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 37.U.K. PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 38.ITALY PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 39.SPAIN PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 40.REST OF EUROPE PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 41.JAPAN PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 42.CHINA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 43.AUSTRALIA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 44.INDIA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 45.SOUTH KOREA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 46.REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 47.BRAZIL PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 48.SAUDI ARABIA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 49.SOUTH AFRICA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 50.REST OF LAMEA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
    FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 55.COMPETITIVE DASHBOARD
    FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 57.ABBOTT LABORATORIES.: NET SALES,($MILLION)
    FIGURE 58.F.HOFFMAN LA ROCHE.: NET SALES ,($MILLION)
    FIGURE 59.THERMOFISCHER INC.: NET SALES,($MILLION)
    FIGURE 60.HOLOGIC INC.: NET SALES ,($MILLION)
    FIGURE 61.BIOMERIEUX SA.: NET SALES ,($MILLION)
    FIGURE 62.QUIDEL CORPORATION.: NET SALES ,($MILLION)
    FIGURE 63.BIO RAD LABORATERIES.: NET SALES,($MILLION)
    FIGURE 64.BECKTON AND DICKINSON COMPANY.: NET SALES,($MILLION)
    FIGURE 65.ADVANDX.: NET SALES ,($MILLION)
    FIGURE 66.BECKMAN COULTER.: NET SALES,($MILLION)

Purchase Full Report of
Pneumonia Testing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue